Abstract
Adult-onset Still's disease (AOSD) is a systemic inflammatory disease of unknown etiology. A 44-year-old male patient presented with AOSD complicated by macrophage activation syndrome after etanercept therapy. His serum tumor necrosis factor-α (TNF-α) level was increased dramatically after etanercept therapy. The clinical course of this case suggests that the increased TNF-α level by etanercept administration might cause macrophage activation syndrome in this case.
MeSH terms
-
Adult
-
Antirheumatic Agents / adverse effects*
-
Etanercept
-
Glucocorticoids / administration & dosage
-
Humans
-
Immunoglobulin G / adverse effects*
-
Immunoglobulins, Intravenous / administration & dosage
-
Inflammation Mediators / blood*
-
Macrophage Activation Syndrome / chemically induced*
-
Macrophage Activation Syndrome / immunology
-
Macrophage Activation Syndrome / therapy
-
Male
-
Methylprednisolone / administration & dosage
-
Plasma Exchange
-
Pulse Therapy, Drug
-
Receptors, Tumor Necrosis Factor
-
Still's Disease, Adult-Onset / drug therapy*
-
Still's Disease, Adult-Onset / immunology
-
Treatment Outcome
-
Tumor Necrosis Factor-alpha / antagonists & inhibitors
-
Tumor Necrosis Factor-alpha / blood*
-
Up-Regulation
Substances
-
Antirheumatic Agents
-
Glucocorticoids
-
Immunoglobulin G
-
Immunoglobulins, Intravenous
-
Inflammation Mediators
-
Receptors, Tumor Necrosis Factor
-
Tumor Necrosis Factor-alpha
-
Etanercept
-
Methylprednisolone